Thus, during the chronic and relatively immunocompetent phase of the infection efficient DC-SIGN use could be an important viral feature selected for, while at severe immunodeficiency, during end-stage disease, the lack of proper antibody responses may result in the emergence of virus variants that instead display enhanced fitness for direct target cell infection. The gene discussed is CD209; the disease is Immunodeficiency.